These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17222126)

  • 1. rFVIIa--for acute rebleeding of a cerebral cavernous malformation.
    Engelhardt K; Brenneis C; Pfausler B; Beer R; Brössner G; Helbok R; Lackner P; Schmutzhard E
    Eur J Neurol; 2007 Jan; 14(1):117-20. PubMed ID: 17222126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.
    Mayo A; Misgav M; Kluger Y; Geenberg R; Pauzner D; Klausner J; Ben-Tal O
    Vox Sang; 2004 Jul; 87(1):34-40. PubMed ID: 15260820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of recombinant activated factor VII in unselected patients with uncontrolled haemorrhage: a single centre experience.
    Payne EM; Brett SJ; Laffan MA
    Blood Coagul Fibrinolysis; 2006 Jul; 17(5):397-402. PubMed ID: 16788316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant factor VIIa in the treatment of bleeding.
    Midathada MV; Mehta P; Waner M; Fink LM
    Am J Clin Pathol; 2004 Jan; 121(1):124-37. PubMed ID: 14750250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa?
    Poon MC
    Curr Hematol Rep; 2003 Mar; 2(2):139-47. PubMed ID: 12901145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cerebral cavernomas in childhood. clinical presentation and diagnosis].
    García-Morales I; Gómez-Escalonilla C; Galán L; Rodriguez R; Simón De Las Heras R; Mateos-Beato F
    Rev Neurol; 2002 Feb 16-28; 34(4):339-42. PubMed ID: 12022048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Off-license" use of recombinant activated factor VII.
    Ghorashian S; Hunt BJ
    Blood Rev; 2004 Dec; 18(4):245-59. PubMed ID: 15501553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma.
    Martinowitz U; Kenet G; Lubetski A; Luboshitz J; Segal E
    Can J Anaesth; 2002 Dec; 49(10):S15-20. PubMed ID: 12546003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
    Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
    Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation.
    Blatt J; Gold SH; Wiley JM; Monahan PE; Cooper HC; Harvey D
    Bone Marrow Transplant; 2001 Aug; 28(4):405-7. PubMed ID: 11571515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidotes to haemorrhage: recombinant factor VIIa.
    Kessler CM
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):183-97. PubMed ID: 15171966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging off-label uses for recombinant activated factor VII: grading the evidence.
    Enomoto TM; Thorborg P
    Crit Care Clin; 2005 Jul; 21(3):611-32. PubMed ID: 15992675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful management of intra-abdominal hemorrhage in the presence of severe alcoholic liver disease with activated recombinant factor VII (rFVIIa; NovoSeven): a case report and review of the literature on approved and off-label use of rFVIIa.
    Agarwal N; Spahr JE; Rodgers GM
    Blood Coagul Fibrinolysis; 2007 Mar; 18(2):205-7. PubMed ID: 17287641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age?
    Rivard GE; Lillicrap D; Poon MC; Demers C; Lépine M; St-Louis J; Warner M
    Haemophilia; 2005 Jul; 11(4):335-9. PubMed ID: 16011584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant activated factor VII (rFVIIa, NovoSeven).
    Agarwal MB; Patnaik M
    J Assoc Physicians India; 2005 Aug; 53():717-20. PubMed ID: 16398083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
    Brenner B; Wiis J
    Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency.
    Tcheng WY; Donkin J; Konzal S; Wong WY
    Haemophilia; 2004 May; 10(3):295-8. PubMed ID: 15086331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Congenital factor VII deficiency: therapy with recombinant activated factor VII -- a critical appraisal.
    Mariani G; Konkle BA; Ingerslev J
    Haemophilia; 2006 Jan; 12(1):19-27. PubMed ID: 16409171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review.
    Mathew P; Young G
    Haemophilia; 2006 Sep; 12(5):457-72. PubMed ID: 16919075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.